RecruitingNCT05590416
A Study of Adalimumab in Acute Vogt-Koyanagi-Harada Disease
Studying Vogt-Koyanagi-Harada disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Tianjin Medical University
- Intervention
- Adalimumab(drug)
- Enrollment
- 15 enrolled
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2021 – 2024
Study locations (1)
- Tianjin Medical University Eye Hospital, Tianjin, Tianjin Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05590416 on ClinicalTrials.gov